TY - JOUR
T1 - A L.E.A.P.S.™ heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection
AU - Goel, N.
AU - Rong, Q.
AU - Zimmerman, D.
AU - Rosenthal, K. S.
N1 - Funding Information:
This research was supported by Public Health Service research grants 2 R44 AI43107-02A1 from NIAID to DZ and KSR. We would like to thank the CMU personnel for their assistance with the animal studies and Dr. D.G. Jarjoura, Ms. V. Androulakakis, Mr. K. Hua for their help with statistical analysis of the data.
PY - 2003/10/1
Y1 - 2003/10/1
N2 - The L.E.A.P.S.™ heteroconjugate vaccine antigen (JgD), composed of a T cell epitope from glycoprotein D (gD8-23) of herpes simplex virus (HSV) linked with a peptide sequence from beta-2-microglobulin (aa38-50), elicited protection against lethal intraperitoneal (IP) challenge and prevented disease signs in most, and limited disease progression, for the rest of BALB/c mice challenged in the epidermal abrasion-zosteriform spread mouse infection model. JgD elicited a Th1 response in vaccinated mice as indicated by delayed type hypersensitivity (DTH) responses to HSV antigen, and gD and virion specific antibodies with an IgG2a/IgG1 >1. Vaccination with the JgD peptide delayed the onset of disease signs, reduced severity of the disease and reduced mortality rates in mice with different MHC backgrounds as compared to their respective control mice. CD8 cells were demonstrated as important for initiation of the immune response to JgD and CD4 cells and interferon gamma (IFN-γ) for delivering immune protection in BALB/c mice, as indicated in monoclonal antibody ablation studies. JgD, and other J-L.E.A.P.S.™ vaccine antigens, appear to prime T cells to initiate a Th1 response, which is subsequently boosted upon viral challenge to result in protection.
AB - The L.E.A.P.S.™ heteroconjugate vaccine antigen (JgD), composed of a T cell epitope from glycoprotein D (gD8-23) of herpes simplex virus (HSV) linked with a peptide sequence from beta-2-microglobulin (aa38-50), elicited protection against lethal intraperitoneal (IP) challenge and prevented disease signs in most, and limited disease progression, for the rest of BALB/c mice challenged in the epidermal abrasion-zosteriform spread mouse infection model. JgD elicited a Th1 response in vaccinated mice as indicated by delayed type hypersensitivity (DTH) responses to HSV antigen, and gD and virion specific antibodies with an IgG2a/IgG1 >1. Vaccination with the JgD peptide delayed the onset of disease signs, reduced severity of the disease and reduced mortality rates in mice with different MHC backgrounds as compared to their respective control mice. CD8 cells were demonstrated as important for initiation of the immune response to JgD and CD4 cells and interferon gamma (IFN-γ) for delivering immune protection in BALB/c mice, as indicated in monoclonal antibody ablation studies. JgD, and other J-L.E.A.P.S.™ vaccine antigens, appear to prime T cells to initiate a Th1 response, which is subsequently boosted upon viral challenge to result in protection.
KW - Herpes simplex virus
KW - JgD-L.E.A.P.S.
KW - Th1 immune response
UR - http://www.scopus.com/inward/record.url?scp=0346186985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346186985&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(03)00429-8
DO - 10.1016/S0264-410X(03)00429-8
M3 - Article
C2 - 14505924
AN - SCOPUS:0346186985
SN - 0264-410X
VL - 21
SP - 4410
EP - 4420
JO - Vaccine
JF - Vaccine
IS - 27-30
ER -
